POST Online Media Lite Edition


Roche gets UK clearance for $4.3 billion Spark takeover

Christian Fernsby |
Roche and Spark Therapeutics announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark.

Article continues below


Pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 2019 as it may be amended and supplemented from time to time.

The offering period of the Offer is scheduled to expire at 5:00 p.m., New York City time, on Monday, December 16, 2019, unless it is extended further under the circumstances set forth in the Agreement and Plan of Merger, dated as of February 22, 2019, by and among Roche Holdings, Inc., 022019 Merger Subsidiary, Inc., and Spark.

What to read next

Roche enters strategic collaboration with Foundation Medicine
Autodesk announces $100 million 3D investment fund
New Zealand rejects Huawei's first 5G bid citing national security risk